Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes

Marina G. Silveira, Jayant A. Talwalkar, Paul Angulo, Keith D. Lindor

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

BACKGROUND: The coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) has been called "overlap syndrome," but diagnosis is challenging and the natural history of this syndrome has not been demonstrated. The importance of the diagnosis of PBC-AIH overlap is due to potential therapeutic options. Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC. METHODS AND RESULTS: We reviewed 135 patients with PBC according to a revised scoring system proposed by the International Autoimmune Hepatitis Group (IAHG). Twenty-six patients had features of PBC-AIH overlap and 109 did not. Mean follow-up was 6.1 yr for overlap syndrome patients and 5.4 yr in PBC patients. There was a higher rate of portal hypertension (P = 0.01), esophageal varices (P < 0.01), gastrointestinal (GI) bleeding (P = 0.02), ascites (P < 0.01), and death and/or orthotopic liver transplantation (OLT) (P < 0.05) in the overlap group. CONCLUSION: In conclusion, esophageal varices, GI bleeding, ascites, and death and/or OLT were more common in the overlap group. The higher risk of symptomatic portal hypertension and worse outcomes in patients with PBC overlap syndrome may justify the risks of immunosuppressive therapy. Large randomized studies are necessary to establish optimal therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)1244-1250
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume102
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Autoimmune Hepatitis
Biliary Liver Cirrhosis
Esophageal and Gastric Varices
Portal Hypertension
Immunosuppressive Agents
Ascites
Liver Transplantation
Hemorrhage
Ursodeoxycholic Acid
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Overlap of autoimmune hepatitis and primary biliary cirrhosis : Long-term outcomes. / Silveira, Marina G.; Talwalkar, Jayant A.; Angulo, Paul; Lindor, Keith D.

In: American Journal of Gastroenterology, Vol. 102, No. 6, 06.2007, p. 1244-1250.

Research output: Contribution to journalArticle

Silveira, Marina G. ; Talwalkar, Jayant A. ; Angulo, Paul ; Lindor, Keith D. / Overlap of autoimmune hepatitis and primary biliary cirrhosis : Long-term outcomes. In: American Journal of Gastroenterology. 2007 ; Vol. 102, No. 6. pp. 1244-1250.
@article{504a3af3e4a3450b8f82acba0cc59c36,
title = "Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes",
abstract = "BACKGROUND: The coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) has been called {"}overlap syndrome,{"} but diagnosis is challenging and the natural history of this syndrome has not been demonstrated. The importance of the diagnosis of PBC-AIH overlap is due to potential therapeutic options. Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC. METHODS AND RESULTS: We reviewed 135 patients with PBC according to a revised scoring system proposed by the International Autoimmune Hepatitis Group (IAHG). Twenty-six patients had features of PBC-AIH overlap and 109 did not. Mean follow-up was 6.1 yr for overlap syndrome patients and 5.4 yr in PBC patients. There was a higher rate of portal hypertension (P = 0.01), esophageal varices (P < 0.01), gastrointestinal (GI) bleeding (P = 0.02), ascites (P < 0.01), and death and/or orthotopic liver transplantation (OLT) (P < 0.05) in the overlap group. CONCLUSION: In conclusion, esophageal varices, GI bleeding, ascites, and death and/or OLT were more common in the overlap group. The higher risk of symptomatic portal hypertension and worse outcomes in patients with PBC overlap syndrome may justify the risks of immunosuppressive therapy. Large randomized studies are necessary to establish optimal therapeutic strategies.",
author = "Silveira, {Marina G.} and Talwalkar, {Jayant A.} and Paul Angulo and Lindor, {Keith D.}",
year = "2007",
month = "6",
doi = "10.1111/j.1572-0241.2007.01136.x",
language = "English (US)",
volume = "102",
pages = "1244--1250",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Overlap of autoimmune hepatitis and primary biliary cirrhosis

T2 - Long-term outcomes

AU - Silveira, Marina G.

AU - Talwalkar, Jayant A.

AU - Angulo, Paul

AU - Lindor, Keith D.

PY - 2007/6

Y1 - 2007/6

N2 - BACKGROUND: The coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) has been called "overlap syndrome," but diagnosis is challenging and the natural history of this syndrome has not been demonstrated. The importance of the diagnosis of PBC-AIH overlap is due to potential therapeutic options. Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC. METHODS AND RESULTS: We reviewed 135 patients with PBC according to a revised scoring system proposed by the International Autoimmune Hepatitis Group (IAHG). Twenty-six patients had features of PBC-AIH overlap and 109 did not. Mean follow-up was 6.1 yr for overlap syndrome patients and 5.4 yr in PBC patients. There was a higher rate of portal hypertension (P = 0.01), esophageal varices (P < 0.01), gastrointestinal (GI) bleeding (P = 0.02), ascites (P < 0.01), and death and/or orthotopic liver transplantation (OLT) (P < 0.05) in the overlap group. CONCLUSION: In conclusion, esophageal varices, GI bleeding, ascites, and death and/or OLT were more common in the overlap group. The higher risk of symptomatic portal hypertension and worse outcomes in patients with PBC overlap syndrome may justify the risks of immunosuppressive therapy. Large randomized studies are necessary to establish optimal therapeutic strategies.

AB - BACKGROUND: The coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) has been called "overlap syndrome," but diagnosis is challenging and the natural history of this syndrome has not been demonstrated. The importance of the diagnosis of PBC-AIH overlap is due to potential therapeutic options. Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC. METHODS AND RESULTS: We reviewed 135 patients with PBC according to a revised scoring system proposed by the International Autoimmune Hepatitis Group (IAHG). Twenty-six patients had features of PBC-AIH overlap and 109 did not. Mean follow-up was 6.1 yr for overlap syndrome patients and 5.4 yr in PBC patients. There was a higher rate of portal hypertension (P = 0.01), esophageal varices (P < 0.01), gastrointestinal (GI) bleeding (P = 0.02), ascites (P < 0.01), and death and/or orthotopic liver transplantation (OLT) (P < 0.05) in the overlap group. CONCLUSION: In conclusion, esophageal varices, GI bleeding, ascites, and death and/or OLT were more common in the overlap group. The higher risk of symptomatic portal hypertension and worse outcomes in patients with PBC overlap syndrome may justify the risks of immunosuppressive therapy. Large randomized studies are necessary to establish optimal therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=34249023304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249023304&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2007.01136.x

DO - 10.1111/j.1572-0241.2007.01136.x

M3 - Article

C2 - 17319931

AN - SCOPUS:34249023304

VL - 102

SP - 1244

EP - 1250

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -